2-(Trifluoromethoxy)phenylacetic acid methyl ester | 666235-35-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(Trifluoromethoxy)phenylacetic acid methyl ester
• 英文别名: methyl 2-[2-(trifluoromethoxy)phenyl]acetate
• CAS: 666235-35-4
• 化学式: C₁₀H₉F₃O₃
• 分子量: 234.175
• InChiKey: AUBPMYGSIDSPTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  5-氨基-1-(4-甲基-3-吡啶基)-1H-吡唑-4-甲酰胺 、 2-(Trifluoromethoxy)phenylacetic acid methyl ester 在 sodium hydride 作用下， 以 乙醇 为溶剂， 以72%的产率得到1-(4-methyl-pyridin-3-yl)-6-(2-trifluoromethoxy-benzyl)-1,5-dihydropyrazolo[3,4-d]pyrimidin-4-one
  参考文献：
  名称：

  [EN] 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS FOR THE TEATMENT OF CNS DISORDERS
  [FR] DÉRIVÉS DE 1,5-DIHYDRO-PYRAZOLO(3,4-D)PYRIMIDIN-4-ONE ET LEUR UTILISATION EN TANT QUE MODULATEURS DE PDE9A POUR LE TRAITEMENT DE TROUBLES DU SNC

  摘要：

  该发明涉及新型取代吡唑吡嘧啶化合物。从化学角度来看，这些化合物的特征由一般式（I）表示：其中R1为苯基或吡啶基，其中任一取代为1到4个，优选为1到3个取代基X；X独立地选自C2-C6-烷基或C1-C6-烷氧基，其中C2-C6-烷基和C1-C6-烷氧基至少经过二卤化至全卤化处理，最好具有2到6个卤素取代基，卤素原子选自氟、氯和溴，最好为氟；R2为苯基或杂环烷基，其中苯基取代为1到3个基团，杂环烷基可选择性地取代为1到3个基团，每种基团独立地选自C1-C6-烷基、C1-C6-烷氧基、羟基羰基、氰基、三氟甲基、氨基、硝基、羟基、C1-C6-烷基氨基、卤素、C6-C10-芳基羰胺基、C1-C6-烷基羰胺基、C1-C6-烷氨基羰基、C1-C6-烷氧羰基、C6-C10-芳基氨基羰基、杂环烷基氨基羰基、杂环烷基羰胺基、C1-C6-烷基磺酰氨基、C1-C6-烷基磺酰基和C1-C6-烷基硫基；这些新化合物可用于制备药物，特别是用于改善患者的感知、注意力、学习和/或记忆的药物。

  公开号：

  WO2009068617A1

文献信息

• COMPOUNDS FOR OPTICALLY ACTIVE DEVICES
  申请人：Merck Patent GmbH

  公开号：EP3363786A1

  公开（公告）日：2018-08-22

  The present invention relates to novel compounds (I) particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic devices comprising such compounds.

  本发明涉及新型化合物 (I)，特别是包含光活性单元的化合物，所述新型化合物特别适用于组合物和眼科设备，以及包含此类化合物的组合物和眼科设备。
• EP3889135A1
  申请人：——

  公开号：EP3889135A1

  公开（公告）日：2021-10-06
• 1, 5-DIHYDRO-PYRAZOLO (3, 4-D) PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MUDULATORS FOR THE TREATMENT OF CNS DISORDERS
  申请人：Eickmeier Christian

  公开号：US20110015193A1

  公开（公告）日：2011-01-20

  The invention relates to novel substituted pyrazolopyrimidines. Chemically, the compounds are characterised by general Formula (I): with R 1 being phenyl or pyridyl, any of which is substituted with 1 to 4, preferably 1 to 3 substituents X; X independently of each other being selected from C 2 -C 6 -alky 1 or Ci-C 6 -alkoxy, where C 2 -C 6 -alkyl and C 1 -C 6 -alkoxy are at least dihalogenated up to perhalogenated. preferably with 2 to 6 halogen substituents, and the halogen atoms being selected from the group of fluoro, chloro and bromo, preferably fluoro; R 2 being phenyl or heteroaryl, where phenyl is substituted by 1 to 3 radicals and heteroaryl is optionally substituted by 1 to 3 radicals in each case independently of one another selected from the group of C 1 -C 6 -alkyI, C 1 -C 6 -alkoxy, hydroxycarbonyl, cyano, trifluoromethyl, amino, nitro, hydroxy, C 1 -C 6 -alkylamino, halogen, C 6 -C 10 -arylcarbonylamino, C 1 -C 6 -alkylcarbonylamino, C 1 -C 6 -alkylaminocarbonyl. C 1 -C 6 -alkoxycarbonyl, C 6 -C 10 -arylaminocarbonyl, heteroarylaminocarbonyl. heteroarylcarbonylamino, C 1 -C 6 -alkylsulphonyl-amino, C 1 -C 6 -alkylsulphonyl and C 1 -C 6 -alkylthio; The new compounds shall be used for the manufacture of medicaments, in particular medicaments for improving, perception, concentration, learning and/or memory in patients in need thereof.
• US8648085B2
  申请人：——

  公开号：US8648085B2

  公开（公告）日：2014-02-11